

Amendments to the Claims

Please amend the claims according to the following listing of the claims.

1 – 34. (Canceled)

35. (Currently Amended) An oral dosage form comprising

- a) at least one active ingredient;
- b) from 20 to 80%, based on the total weight of the dosage form, of a formulated mixture comprising polyvinyl acetate and polyvinylpyrrolidone;
- c) an additive selected from the group consisting of
  - c1) from 1 to 40%, based on the total weight of the dosage form, of a water-soluble non-swelling polymer,
  - c2) from 1 to 40%, based on the total weight of the dosage form, of a water-soluble swelling polymer,
  - c3) from 1 to 40%, based on the total weight of the dosage form, of a lipophilic additive,  
and combinations thereof; and
- d) optionally an excipient,

wherein component c) does not consist of a component cellulose acetate phthalate alone or in combination with one or more components selected from the group consisting of stearic acid, cellulose acetate phthalate, magnesium stearate, and combinations thereof.

36. (Previously Presented) The oral dosage form of claim 35, wherein the amount of active ingredient released from the oral dosage form in the first hour is limited to 25.3%, measured according to USP XXIV paddle method.

37. (Previously Presented) The oral dosage form of claim 35, wherein the oral dosage form has a hardness determined with a Krämer tablet tester (HAT-TMB) greater

than or equal to 244 N.

38. (Previously Presented) The oral dosage form of claim 35, wherein the oral dosage form has a friability determined in an Erweka Friabilator of less than 3%.

39. (Previously Presented) The oral dosage form of claim 35, wherein the ratio of polyvinyl acetate to polyvinylpyrrolidone in the polymeric mixture is from 6:4 to 9:1.

40. (Previously Presented) The oral dosage of claim 35, wherein the water-soluble non-swelling polymer, if present, is selected from the group consisting of polyvinyl alcohols, polyethylene glycols, polyoxyethylene/polyoxypropylene block copolymers, polyvinylpyrrolidones, polyvinylpyrrolidone derivatives, vinyl acetate/vinylpyrrolidone copolymers, and combinations thereof.

41. (Previously Presented) The oral dosage of claim 35, wherein the water-soluble non-swelling polymer, if present, is selected from the group consisting of polyethylene glycols, polyvinylpyrrolidones, vinyl acetate/vinylpyrrolidone copolymers, maltodextrins, and combinations thereof.

42. (Previously Presented) The oral dosage of claim 35, wherein the water-soluble swelling polymer, if present, is selected from the group consisting of alginates, pectins, galactomannans, carrageenans, dextran, curdlan, pullulan, gellan, chitin, gelatin, xanthans, hemicelluloses, cellulose derivatives, starch derivatives, polyacrylic acid, polymethacrylic acid, acrylic acid/methacrylic acid copolymers, salts thereof, and combinations thereof.

43. (Previously Presented) The oral dosage of claim 42, wherein the water-soluble swelling polymer, if present, is a cellulose derivative selected from the group consisting of methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylhydroxyethylcellulose,

carboxymethylcellulose, carboxymethylstarch, degraded starch, and combinations thereof.

44. (Previously Presented) The oral dosage of claim 43, wherein the water-soluble swelling polymer, if present, is hydroxypropylmethylcellulose.
45. (Previously Presented) The oral dosage form of claim 35, wherein the lipophilic additive, if present, is selected from the group consisting of cellulose derivatives, acrylic ester/methacrylic ester copolymers, fatty alcohols, fatty acids, fatty acid esters, fatty alcohol esters, glycerides, waxes, lecithin, and combinations thereof.
46. (Previously Presented) The oral dosage form of claim 45, wherein the lipophilic additive, if present, is a cellulose derivative selected from the group consisting of cellulose acetate succinate, hydroxypropylmethylcellulose acetate phthalate, and hydroxypropylmethylcellulose acetate succinate.
47. (Previously Presented) The oral dosage form of claim 45, wherein the lipophilic additive, if present, is an acrylic ester/methacrylic ester copolymer selected from the group consisting of methyl methacrylate/ethyl acrylate copolymers, ammoniomethacrylate copolymers type A and type B, methacrylic acid/acrylic ester copolymers, and methacrylic acid/ethyl acrylate copolymers.
48. (Previously Presented) The oral dosage form of claim 35, wherein the at least one active ingredient is selected from the group consisting of food supplements, food additives, vitamins, minerals, trace elements, active pharmaceutical ingredients, and combinations thereof.
49. (Previously Presented) The oral dosage form of claim 35, wherein the at least one active ingredient is selected from the group consisting of benzodiazepines, antihypertensives, vitamins, cytostatics, anesthetics, neuroleptics, antidepressants, antibiotics, antimycotics, fungicides, chemotherapeutics, urologicals, platelet

aggregation inhibitors, sulfonamides, spasmolytics, hormones, immunoglobulins, sera, thyroid therapeutics, psychopharmaceuticals, antiparkinson agents and other antihyperkinetics, ophthalmologicals, neuropathy products, calcium metabolism regulators, muscle relaxants, lipid-lowering agents, liver therapeutics, coronary agents, cardiac agents, immunotherapeutics, regulatory peptides and their inhibitors, hypnotics, sedatives, gynecologicals, antigout agents, fibrinolytics, enzyme products and transport proteins, enzyme inhibitors, emetics, perfusion promoters, diuretics, diagnostics, corticoids, cholinergics, biliary therapeutics, antiasthmatics, bronchospasmolytics, beta-receptor blockers, calcium channel blockers, ACE inhibitors, arteriosclerosis remedies, antiinflammatory agents, anticoagulants, antihypotensives, antihypoglycemics, antifibrinolytics, antiepileptics, antiemetics, antidotes, antidiabetics, antiarrhythmics, antianemics, antiallergics, anthelmintics, analgesics, analectics, aldosterone antagonists, weight-reducing agents, and combinations thereof.

50. (Previously Presented) The oral dosage form of claim 35, wherein the oral dosage form is a tablet, an extrudate, a pellet, or a granulate.
51. (Previously Presented) The oral dosage form of claim 35, wherein the oral dosage form is produced by direct compression, extrusion, melt extrusion, pelleting, compaction, or wet granulation.
52. (Previously Presented) The oral dosage of claim 35, wherein the excipient is selected from the group consisting of a binder, an extender/filler, a disintegrant, a lubricant, a flow regulator, a dye, a stabilizer, and combinations thereof.
53. (Previously Presented) The oral dosage of claim 57, wherein the stabilizer comprises a component selected from the group consisting of an antioxidant, a wetting agent, a preservative, a release agent, a flavoring, a sweetener, and combinations thereof.

54. (Previously Presented) The oral dosage form as claimed in claim 35, wherein a water-soluble or water-insoluble release-delaying coating is applied to the oral dosage form.

55. (Previously Presented) An oral dosage form comprising

- a) at least one active ingredient;
- b) from 20 to 80%, based on the total weight of the dosage form, of a formulated mixture comprising polyvinyl acetate and polyvinylpyrrolidone;
- c) from 1 to 40%, based on the total weight of the dosage form, of a water-soluble swelling polymer;
- d) optionally from 1 to 40%, based on the total weight of the dosage form, of a water-soluble non-swelling polymer;
- e) optionally from 1 to 40%, based on the total weight of the dosage form, of a lipophilic additive; and
- f) optionally an excipient.

56. (Previously Presented) The oral dosage form of claim 55, wherein the water-soluble swelling polymer is selected from the group consisting of hydroxypropylmethylcellulose, and methylhydroxyethylcellulose.

57. (Previously Presented) An oral dosage form comprising

- a) at least one active ingredient;
- b) from 20 to 80%, based on the total weight of the dosage form, of a formulated mixture comprising polyvinyl acetate and polyvinylpyrrolidone;
- c) an additive selected from the group consisting of
  - c1) from 1 to 40%, based on the total weight of the dosage form, of a water-soluble non-swelling polymer,

- c2) from 1 to 40%, based on the total weight of the dosage form, of a water-soluble swelling polymer,
- c3) from 1 to 40%, based on the total weight of the dosage form, of a lipophilic additive,  
and combinations thereof; and
- d) optionally an excipient,

wherein the formulated mixture is prepared by spray-drying a dispersion comprising polyvinyl acetate and polyvinylpyrrolidone.